Lol-Ox:
A phase II proof of concept trial, randomized, double-blind, dose escalation, evaluating the activity of oxfendazole for the treatment of Loiasis. The overall aim is to develop a treatment of to reduce loiasis transmission.
LoaCare:
Clinical management of loiasis in high transmission regions of Gabon. A phase 3 clinical trial to evaluate the efficacy, safety, and tolerability of different treatment regimens in individuals with microfilaremic loiasis and individual with occult loiasis for the reduction of microfilareamia and /or for the reduction of Loa loa associated symptoms and signs endemic regions of Gabon. The aim is to evaluate Loa loa regimens treatment used in endemic area and to evaluate several diagnostic techniques for the detection of Loa loa.
RepChrys-Loa:
Evaluation of arthropod repellents in their efficacy to avoid Chrysops bites in a high transmission region for loiasis in Gabon. The aim is to reduce Loa loa transmission.
PARASAFE:
A phase II, multi-country, randomized, placebo-controlled, double blinded adaptive platform trial to assess the efficacy and safety of oxfendazole in adults with trichuriasis, and/or mansonellosis, and/or onchocerciasis and/or loiasis. The overall aim is to develop a pan nematocidal for the treatment of helminth in endemic African area including onchocerciasis, loiasis, mansonellosis, trichuriasis.
PARASAFE is part of ewhorm project funded by the European and Developing Countries Clinical Trials Partnership 3 (EDCTP3) program supported by the European Union (EU).
CAPTURE-1:
A Phase IIa Proof of Concept, Multicenter, Randomized, Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Combination M5717 plus Pyronaridine Administered Once Daily for 1 or 2 Days to Adults and Adolescents with Acute Uncomplicated. The main objective is to develop single dose or two days doses of efficacious medicines for treatment of malaria in Africa.
Capture-1 is part of Pamafrica project funded by the European and Developing Countries Clinical Trials Partnership 2 (EDCTP2) program supported by the European Union (EU).
KALUMI:
A Phase 2 interventional, multicenter, randomized, openlabel study in three age-descending cohorts to evaluate efficacy, safety and tolerability of KAF156 and Lumefantrine-SDF combination, under fasted or fed conditions, in the treatment of acute uncomplicated Plasmodium falciparum Malaria in a paediatric population.
Kalumi is part of WANECAII project funded by the European and Developing Countries Clinical Trials Partnership 2 (EDCTP2).
KALUMA:
A phase III clinical trial, randomized, open-label, multicenter study to compare efficacy, safety and tolerability of KLU156 with Coartem® in the treatment of uncomplicated Plasmodium falciparum malaria in adults and children ≥ 5 kg body weight followed by an Extension phase with repeated KLU156 treatment. The main objective is to develop three days doses non artemisin combinaison therapy of efficacious medicines for treatment of malaria in Africa.
